Skip to main content

Johnson & Johnson Anticipates COVID Vaccine Sales Of $2.5 Billion In 2021

Johnson & Johnson is expecting its COVID-19 vaccine to reach $2.5 billion in sales this year, despite concerns about the injection’s efficacy against the dreaded Delta variant.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.